Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 31.48
-0.68 (-2.11%)
Jan 21, 2026, 12:43 PM CET
Hansa Biopharma AB Market Cap
Hansa Biopharma AB has a market cap or net worth of 3.27 billion as of January 21, 2026. Its market cap has increased by 23.11% in one year.
Market Cap
3.27B
Enterprise Value
3.94B
Revenue
178.61M
Ranking
n/a
PE Ratio
n/a
Stock Price
31.48
Market Cap Chart
Since April 24, 2008, Hansa Biopharma AB's market cap has increased from 30.71M to 3.27B, an increase of 10,556.00%. That is a compound annual growth rate of 30.08%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 20, 2026 | 3.27B | -6.40% |
| Dec 30, 2025 | 3.50B | 31.53% |
| Dec 30, 2024 | 2.66B | 93.47% |
| Dec 29, 2023 | 1.37B | -46.77% |
| Dec 30, 2022 | 2.58B | -34.64% |
| Dec 30, 2021 | 3.95B | -63.06% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vicore Pharma Holding AB | 3.16B |
| Saniona AB | 2.93B |
| Flerie AB | 2.90B |
| BioInvent International AB | 1.82B |
| Egetis Therapeutics AB | 1.75B |
| Diamyd Medical AB | 1.67B |
| Genovis AB (publ.) | 1.39B |
| Cantargia AB | 1.25B |